Riskpilot← Back to searchSign inGet full accessDesitin Pharma AB
ABActiveOrg 5565431995Desitin Pharma Ab Box 2064Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19971 employees
Revenue 2024
SEK 6M
-27% vs 2023
EBITDA margin
9.7%
-30% vs 2023
Equity ratio
81.0%
Financial strength
Net profit 2024
SEK 455K
-29% vs 2023
| Revenue | SEK 6M | -27% |
| EBITDA | SEK 576K | -30% |
| Net profit | SEK 455K | -29% |
| Total assets | SEK 6M | -35% |
| Equity | SEK 4,9M | +10% |
| Employees | 1 | — |
Legal name
Desitin Pharma AB
Org number
5565431995
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
13 juni 1997
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-09-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Bloching, Philipp Andreas Firman tecknas av Lønne, Eli Thieken, Katrin Elisabeth i förening med en av ledamöternaDessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva handel och marknadsföring av läkemedel samt därmed förenlig verksamhet.
Address
Desitin Pharma Ab Box 2064
Email
eli.lonne@desitin.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 1 739 | 2 468 | 9 193 | 12 019 | 11 374 | 8 178 | 5 952 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 215 | 314 | −250 | 510 | 295 | 1 064 | 1 656 | 1 431 | 818 | 576 |
| Depreciation & amort. | −27 | −22 | −36 | −38 | −46 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 188 | 292 | −286 | 472 | 249 | 1 064 | 1 656 | 1 431 | 818 | 576 |
| Net financials | 3 | −1 | 8 | −10 | −56 | −61 | −59 | −42 | 1 | — |
| Profit before tax | 441 | 514 | 1 | 762 | 193 | 1 003 | 1 596 | 1 388 | 819 | 575 |
| Tax | −98 | −114 | −1 | −170 | −42 | −218 | −348 | −295 | −180 | −120 |
| Net profit | 343 | 400 | 0 | 592 | 151 | 785 | 1 248 | 1 093 | 639 | 455 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2 951 | 1 825 | 1 569 | 1 832 | 3 818 | 5 600 | 6 359 | 5 843 | 9 217 | 6 003 |
| Equity | 1 602 | 1 052 | 1 051 | 1 644 | 1 794 | 2 580 | 3 828 | 4 621 | 4 409 | 4 865 |
| Long-term debt | 0 | 0 | 0 | 0 | 1 625 | 1 638 | 1 095 | 0 | 0 | 0 |
| Short-term debt | 548 | 194 | 218 | 188 | 398 | 1 382 | 1 436 | 1 223 | 4 808 | 1 138 |
| Total debt | 548 | 194 | 218 | 188 | 2 023 | 3 020 | 2 531 | 1 223 | 4 808 | 1 138 |
EBITDA margin
9.7%
This company
15.8%
Market median
-39% vs market
20152024
Equity ratio
81.0%
This company
38.2%
Market median
+112% vs market
20152024
Return on equity
9.4%
This company
18.4%
Market median
-49% vs market
20152024
Net profit margin
7.6%
This company
8.1%
Market median
-6% vs market
20152024
Asset turnover
0.99×
This company
1.12×
Market median
+12% vs market
20152024
Debt / equity
0.23×
This company
0.62×
Market median
+63% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-10-01 – 2020-09-30
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-10-01 – 2019-09-30
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-10-01 – 2018-09-30
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-10-01 – 2017-09-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-10-01 – 2016-09-30
- Annual report 2015Filed via Bolagsverket / SCB · Period 2014-10-01 – 2015-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AA Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
LM Chief Auditor | Chief Auditor | 2024 | — | — |
EL Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
PG Authorized Recipient of Service | Authorized Recipient of Service | 2020 | — | — |
IL Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
DESITIN ARZNEIMITTEL GMBH | Company | 100.0% | 100.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
DESITIN ARZNEIMITTEL GMBH
Desitin Pharma AB (this company)Board members of Desitin Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Alexander Arnkværn Berg | Chief Executive Officer | 0 companies |
| Lajos Mathias Constantin Racz | Chief Auditor | 0 companies |
| Eli Lønne | Chief Executive Officer | 0 companies |
| Philipp Grymer | Authorized Recipient of Service | 0 companies |
| Ingvar Lars-Göran Larsson | Chief Auditor | 0 companies |
| Katrin Elisabeth Thieken | Board of Directors | 0 companies |
| Christian Eric Schmolck | Board of Directors | 0 companies |
| Philipp Andreas Bloching | Chairman | 0 companies |
| Christoph Steinschulte | Board of Directors | 0 companies |
| Martin Schuett | Chairman | 0 companies |